EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  • STATUS
    Recruiting
  • End date
    Oct 31, 2022
  • participants needed
    6000
  • sponsor
    Boehringer Ingelheim
Updated on 2 June 2021
Investigator
Boehringer Ingelheim Call Center
Primary Contact
Kelowna General Hospital (1.0 mi away) Contact
+314 other location
nephropathy

Summary

The primary aim of the study is to investigate the effect of empagliflozin on kidney disease progression or cardiovascular death versus placebo on top of standard of care in patients with pre-existing chronic kidney disease

Details
Condition chronic renal insufficiency, Chronic renal failure, chronic kidney disease, chronic kidney disease (ckd)
Treatment Matching Placebo, Empagliflozin
Clinical Study IdentifierNCT03594110
SponsorBoehringer Ingelheim
Last Modified on2 June 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note